Crinetics Pharmaceuticals Inc 's (CRNX) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Crinetics Pharmaceuticals Inc   (NASDAQ: CRNX)
 



  Crinetics Pharmaceuticals Inc Outlook

On February 28 2024 the Crinetics Pharmaceuticals Inc provided following guidance

Crinetics Pharmaceuticals Inc. released their financial results for the fourth quarter and full year of 2023 along with a corporate update. The company is eagerly awaiting the topline results of their Phase 3 PATHFNDR-2 study, which are expected to be released in March 2024. These results will determine the next steps for the company, including the submission of a New Drug Application (NDA) for a potential treatment for Acromegaly, which is anticipated in the second half of 2024.

The company is optimistic about the potential of their new treatment and is looking forward to the results of the upcoming study. They are committed to advancing their research and development efforts in order to bring innovative therapies to patients in need. Overall, Crinetics Pharmaceuticals is focused on driving growth and delivering value to shareholders in the coming years.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.